Clinical and Sociodemographic Correlates of Poor Medication Adherence in Bipolar Disorder
Poor medication adherence bipolar disorder is linked to factors such as substance use, younger age, and lower illness insight. This review identifies key correlates to guide clinical screening. Addressing these factors may reduce relapse risk in bipolar…
GLP-1 Receptor Agonist: Weight Loss Clinical Evidence
Oral GLP-1 medications offer a promising alternative to injectable therapies for sustained weight loss. Clinical evidence supports their role in improving medication adherence. These options expand treatment choices for patients managing obesity and…
GLP-1 Weight Loss Medicine: Clinical Evidence & Access
GLP-1 weight loss access is transforming how patients obtain medications for obesity management. This shift impacts medication adherence and telehealth delivery models. Understanding clinical evidence is key for effective patient care.
Avoiding the Biggest Clinical Mistakes in GLP-1 Receptor Agonist Use
GLP-1 receptor agonist clinical mistakes often reduce treatment effectiveness and safety. Patients frequently discontinue therapy prematurely or mismanage dosing. Recognizing and addressing these errors is essential for optimal weight management outcomes.
Push to Repeal New York Medical Cannabis Tax Amid ‘Crisis’ Claims
The New York medical cannabis tax repeal is a critical issue affecting patient access and affordability. This tax increases out-of-pocket costs, potentially reducing medication adherence. Clinicians should consider these financial barriers when…
Topical Cannabis for AIMSS: Cannabinoid Clinical Trials
Topical cannabis balms for AIMSS were tested in a randomized trial for breast cancer patients experiencing joint pain from aromatase inhibitor therapy. The study assessed feasibility and safety of cannabinoid topical treatments. Results provide early…
